Background: Heart failure is a growing problem worldwide with high degree of morbidity and mortality especially in those with dilated cardiomyopathy. We hypothesized that noninvasive bi level positive airway pressure ventilation (BIPAP) could play a crucial role in those patients.
Introduction
HEART failure is a disease with high incidence and prevalence in the population. The costs with hospitalization for decompensated heart failure reach approximately 60% of the total cost with heart failure treatment, and mortality during hospitalization varies according to the studied population, and could achieve values of 10% [1] .
Decompensated heart failure (DHF) is a clinical syndrome in which a structural and/or functional change in the heart and leads to its inability to eject and/or accommodate blood, which causing a functional limitation and requiring immediate therapeutic intervention [2] . The initial objective of the treatment of DHF is to achieve hemodynamic and symptomatic improvement [3] .
Many patients may improve with conventional medical treatments using simple oxygen mask, diuretics, and vasodilators. However, despite endotracheal intubation may be complicated by aspiration, laryngeal injury and others [4] but "invasive" mechanical ventilatory support (through endotracheal intubation) is required and may be preferable if respiratory distress cannot be alleviated quickly.
Positive airway pressure is said to have its own Preferential hemodynamic effects in patients with chronic heart failure as it increases intrapleural and pericardial pressure, which decreases venous return (i.e., preload) and transmural myocardial pressure (i.e., afterload).Subsequently, there are reductions in ventricular diameter and functional mitral regurgitation and improvements in cardiac output, besides improvements in pulmonary mechanics include greater alveolar recruitment with decreased shunting and increase inpulmonary compliance [5] .
Bi-level positive airway pressure (BiPAP), a non-invasive ventilation modality (NIV) provides two different levels pressure, higher airway pressures are applied during inspiration and lower during expiration. A number of studies have demonstrated beneficial effects of BiPAP in acute asthma, and severe pneumonia, With BiPAP, the inspiratory pressures (IPAP) must be set separately from the expiratory pressures (EPAP). Generally, the IPAP settings start at 8-10cm H2O, and can range from 4 to 24cm H2O. The EPAP settings typi-callystart at 2-4cm H2O, and range from 2 to 20cm H2O.
These initial settings aim to optimize patient tolerance and Discontinuing NIV generally requires a "weaning" period. During this time, nearby observation of the patient is essential. Indications for weaning the NIV include general patient stability, consistent oxygenation > 90%-92% with 4L/minute (or less) of supplemental oxygen, and a respiratory rate <25. The weaning process of decreasing the pressure settings should generally parallel the process by which pressures increased: If several increments of increase were used, the reverse should hold true for the weaning process. Consider resuming or increasing the NIV if the respiratory rate increases to >30, oxygen saturation drops below 90% (despite 4L/minute of oxygen), or if the PaCO2 increases by at least 5mmHg. Sudden or severe deteriorations warrant consideration of conventional intubation techniques and mechanical ventilation [6] .
Patients and Methods
In a prospective randomized controlled interventional study, Forty adult patients, aged between 18-83 years, of both sexes, and normal body weight, (BMI=25-35). This study was approved by the local Ethics Committee, Faculty of Medicine, Assiut University during 2017. All the patients or one of their accompanies provided oral and written consents. Patients were admitted to the Critical Care Unit of Internal Medicine Department, Assiut University Hospital, by manifestation of decompensated heart failure (NYHA III-IV, ACC/AHA stage C-D) [7,8] such as dyspnea, PND, orthopnea, raised JVP, bilateral basal crackles, laterally displaced apical impulse, bilateral lower limb edema due to dilated cardiomyopathy (EF=LVEF <35%).
Exclusion criteria:
• Any chest disease (Severe acute or chronic airway or parynchymal diseases). • Valvular heart disease other than functional regurge.
• Ventricular arrhythmias.
• Immediate indication for tracheal intubation [10] : (=Rescue ventilator support in case of failed NIV): -Cardiogenic shock: Systolic blood pressure <90mmHg. -SpO2 <80 % on FIO2=1.
-PH less than 7.25, PCO 2 more than 55m mHg.
-Altered mental state.
-Cardiac or respiratory arrest.
Patients were divided into:
Group A (Study group, n=20): Patients received the standard medical therapy for heart failure (such as diuretics, ACE inhibitor, and digoxin) and supported NIV through BIPAP.
Group B (Control group, n=20): Included patients who received the standard medical therapy for heart failure only with the conventional oxygen therapy through oxygen mask.
Randomization was done by computer-generated table, all participants were subjected to full history taking and full physical examination including vitals, chest and meticulous cardiovascular examination. ECG monitoring for any new changes, or arrest, and Plain Chest X-ray for presence of increased cardiothoracic ratio, prominent bronchovascular markings.
Treatment modalities:
Group (A) patients received the standard medical therapy for heart failure (like that for group B) in the form of diuretics (furosemide 20-240mg daily, spironolactone 25-50mg daily), angiotensine converting enzyme inhibitors (ramipril 2.5-10mg daily) and vasodilators (if needed such as nitroglycerin ...) plus supported non-invasive ventilation through BIPAP. The BIPAP use was in intermittent sessions each of 2 hours for 2 consecutive days. The mean duration of BIPAP use was 8 hours daily. The first session was during the first 4 hours of starting the therapy. Group (B) patients received the standard medical therapy for heart failure (like that for group A), plus oxygen venture-mask 40%, and changed according to Sao2 for 48 hour.
• Rescue ventilatory support: Failure of oxygen therapy or Non Invasive BIPAP therapy inany patient is an indication for immediate intubation and invasive mechanical ventilation as mentioned above. • Rescue circulatory support: In case of hemodynamic instability, such as decreased SBP <90mmhg, or 25% of basic reading, we will initiate dopamine or dobutamine inotropic support (± isosorbide dinitrite). For both groups: Vital signs were recorded at baseline, after 4 hours and after 48 hours.
Statistical analysis:
All analyses were performed using the IBM SPSS 20.0 software. The data were tested, at first, for normality using the Shapiro-Wilk test, and for homogenecity variances prior to further statistical analysis. Categorical variables were described by number and percent (N, %), while the continuous variables were described by mean and standard deviation (Mean, SD, Median). Chi-square test and fisher exact test used to compare between categorical variables, while compare between continuous variables by t-test for normally distributed data and Mann Whitney U for abnormally distributed data. A two-tailed p<0.05 was considered statistically significant.
Results
There was no statistically significant differences between both groups as regard to the age, gender, and co-morbidities, as shown in Tables (1, 2) .
While there was a statistically significant reduction in the length of stay in the group A patients versus group B (4.6 ±0.3 vs. 5.1 ±0.8 days), with a p-value=0.013 (Table 2) .
Despite there was no statistically significant difference between the two groups of the study, as regarded to dyspnea after 48 hours (p=0.246), but there was significant improvement in tachypnea in group A; as well as there was improvement within each group using paired t-test, (Table 3) .
After 48 hours, there was statistically significant improvement in the hemodynamics and clinical parameters compared to the baseline readings in both groups. When compared both groups, there was statistically significant difference between both groups as regard to the percentage changes of SBP, and DBP, with p-values (=0.033, 0.022) respectively, without a significant differences between that of the HR (p=0.099) ( Table 4 ).
All patients were cooperative and accepted the line of treatment, especially those received the NIPPV through bi level positive pressure ventilation (group A).
There was no statistically significant difference between both groups regarding the incidence of mortality, during the study. However, one patient of each group died because of cardiogenic shock, within two days, after the end of the study. The patient from group A was admitted with decompensated heart failure and blood pressure of (100/65), after 2 days the patient became hypotensive, so that, we stopped diuretics and added inotropic and vasoactive supporting measures, eventually he was intubated and mechanically ventilated for 3 days then died in asystole. The patient from group B was admitted with decompensated heart failure, jaundice and blood pressure was 95/65. Similarly, the patient became hypotensive within 2 days. Despite of stopping diuretics and adding inotropic and vasoactive measures, but he was intubated and mechanically ventilated for 2 days then died. 
Discussion
In our study we found significant differences between patients who received BIPAP plus medical treatment (group A) and those received medical treatment only plus intermittent oxygen mask (group B) as regard to the clinical and heamodynamic changes with more improvement of those parameters in group A. As regard to dyspnea, group A also, showed dramatic and rapid improvement of dyspnea after 4 hours from starting treatment, but both modalities of treatment became nearly equally effective after 48 hours. Improvement of dyspnea was consequently accompanied with significant improvement in respiratory ratet between the two groups. Respiratory rate was decreased in both groups but significantly in group A after 4 hours from baseline and after 48 hours from baseline despite there was significant difference between both groups as regard baseline respiratory rate as it was higher in group A but improvement (decrement) was significant more in group A at 4 and 48 hours.
Despite we found a statistically significant drop in both SBP, and DBP, after 4 and 48 hours, but it was of no significant clinical importance. (May be due to the decreased sympathetic stimulation because of dyspnea, beside the stress of hospitalization and admission to the critical care unit). However, we used lower values of BiPAP (8-12/4-5) . There-fore, this must be taken into consideration as the higher values, and or the hypotensive patients may get worse after BIPAP therapy.
Regarding heart rate, Inspite of a decrease in heart rate in both groups (more in group A), there was no statistically significant difference between both groups at 4 hours ( p=0.727) or 48 hours (p= 0.099), and it was also of no clinical importance.
Vital and colleagues in their Cochrane Database (2008), supported the use of NIPPV versus traditional therapy in heart failure and cardiogenic pulmonary edema and showed statistically significant decreased risk of intubation, as well as decreased in-hospital mortality [9] .
To our knowledge, there were few studies has been done demonstrating the effect of BIPAP on clinical, heamogasometric and echocardiographic parameters in patients with decompensated heart failure (NYHA III-IV, ACC/AHA stage C-D) due to dilated cardiomyopathy.
Brick et al., [10] have studied fourteen patients (9 men and 5 women) with stable chronic CHF with left ventricular ejection fraction <35% were subjected to Bilevel positive airway pressure via nasal mask at an inspiratory pressure of 5cm H 2O and an expiratory pressure of 3cmH 2 O on spontaneous mode at room air for 1h. Baseline clinical and echocardiographic parameters were compared with the same parameters after 1h of bilevel positive airway pressure. Statistically significant decreases were noted in these mean values: Systolic BP (p<0.008), heart rate ( p<0.002), respiratory rate (p<0.001), and systemic vascular resistance (p<0.001). Statistically significant increaseswere noted in these mean values: Cardiac output from 5.09 to 6.37 L/min (p 5 0.004), ejection fraction from 28.71% to 34.36% (p<0.001), and enddiastolic volume from 224.36 to 246.2 1mL (p< 0.045). And this correlate with our results.
On the other hand, Levitt et al., [11] enr-olled 38 patients who were in severe CHF. Patients were randomized to receive either BiPAP or O 2 therapy in addition to adjunct therapy. Heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate were recorded at 30min, 60min, and 120min for all patients, the ABG was obtained at 60min and 120min after the baseline ABG. Age and gender were not different between the groups. Heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, and pulse oximetry all showed no statistically significant difference in change over time between both groups, but there was a statistically significant change over time within each group including intubation rate and AMI frequency but he didn't told about inclusion and exclusion criteria of his patients as well as the setting and mode of BIPAP which was used.
Despite the most of other studies were carried out in patients with cardiogenic pulmonary edema and the difference between BIPAP and CPAP in this setting, most of them agree with our results as regard clinical, heamdynamic effects eg [12] [13] [14] [15] [16] [17] [18] .
The more advancement in technology, solved some problems related to the use of BIPAP, In the past with CPAP, facial skin necrosis with prolonged use was considered a problem; however, with soft mask cushions and stoma paste, this is no longer a problem. BiPAP can also be applied nasally, with a specially configured, smaller mask. This improves patient comfort and allows greater ease of access for clearing airway secretions. CPAP requires a very cooperative patient and loses much of its effectiveness whenever a significant mask leak is present. BiPAP, however, is more leak tolerant and therefore can be used in less cooperative patients with better results and for longer periods. With all NIV modalities, the patient controls the tidal volume and breathing frequency; despite, newer BiPAP delivery devices have highly sensitive, flow triggered inspiratory valves that reduce both the patient effort and the time from breath initiation to the delivery of assistance.
IN our study, there were still, some obstacles related to the availability of the recent devices, the low personal experience with the use of BiPAP, the small number of the patient, and the study of the chronic effects of the long term use of those category of patients necessities the need for more further studies to be done.
Conclusion:
We concluded that the use of Non-Invasive Bilevel Positive Airway Pressure ventilation with the standard medical treatment significantly improved Clinical, respiratory, with a limited hemodynamic effects, in patients with decompensated heart failure due to dilated cardiomyopathy, more than the use of the usual oxygen therapy plus the standard medical therapy with no significant differences concerning morbidity and mortality rates.
The cooperation between different health care providers such as the internal medicine physicians, emergency medicine-physicians, intensivists, respiratory therapists, and well-trained nursing staff together will improve the service and help better management for the critically ill patients such as those with decompensated heart failure and dilated cardiomyopathy.
Lastly, we concluded that, "BiPAP is not only a safe adjuvant to the conventional treatment but also; it can be more advantageous in the management of patients with dilatedcardiomyopathy with decompensated heart failure".
